Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
EDQM
0
USP
0
JP
0
Others
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
API
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. 2383086-06-2
2. Bgb-11417
3. Bgb11417
4. 30r67u9kys
5. Bgb 11417
6. N-[4-[(4-hydroxy-4-methylcyclohexyl)methylamino]-3-nitrophenyl]sulfonyl-4-[2-[(2s)-2-(2-propan-2-ylphenyl)pyrrolidin-1-yl]-7-azaspiro[3.5]nonan-7-yl]-2-(1h-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide
7. 98i
8. Sonrotoclax [inn]
9. Sonrotoclax [who-dd]
10. Sonrotoclax (usan/inn)
11. Sonrotoclax [usan]
12. Orb1982765
13. Chembl5314951
14. Chembl5560668
15. Schembl23457665
16. Schembl24774450
17. Schembl30658625
18. Gtpl13354
19. Bdbm567682
20. Bdbm567800
21. Glxc-27922
22. Ex-a8026
23. Us11420968, Example F43
24. Us11420968, Example F48
25. Bdbm50636456
26. Nsc856894
27. At48034
28. Nsc-856894
29. Compound 12e [pmid: 38695063]
30. Da-58000
31. Hy-148026
32. Cs-0572444
33. D12883
34. 2-((1h-pyrrolo[2,3-b]pyridin-5-yl)oxy)-n-((4-((((1r,4r)-4-hydroxy-4-methylcyclohexyl)methyl)amino)-3-nitrophenyl)sulfonyl)-4-(2-((s)-2-(2-isopropylphenyl)pyrrolidin-1-yl)-7-azaspiro[3.5]nonan-7-yl)benzamide
35. 2-((1h-pyrrolo[2,3-b]pyridin-5-yl)oxy)-n-((4-(((trans-4-hydroxy-4-methylcyclohexyl)methyl)amino)-3-nitrophenyl)sulfonyl)-4-(2-((s)-2-(2-isopropylphenyl)pyrrolidin-1-yl)-7-azaspiro[3.5]nonan-7-yl)benzamide
36. Benzamide, N-[[4-[[(trans-4-hydroxy-4-methylcyclohexyl)methyl]amino]-3-nitrophenyl]sulfonyl]-4-[2-[(2s)-2-[2-(1-methylethyl)phenyl]-1-pyrrolidinyl]-7-azaspiro[3.5]non-7-yl]-2-(1h-pyrrolo[2,3-b]pyridin-5-yloxy)-
37. N-(4-{[(trans-4-hydroxy-4-methylcyclohexyl)methyl]amino}-3-nitrobenzene-1-sulfonyl)-4-(2-{(2s)-2-[2-(propan-2-yl)phenyl]pyrrolidin-1-yl}-7-azaspiro[3.5]nonan-7-yl)-2-[(1h-pyrrolo[2,3-b]pyridin-5-yl)oxy]benzamide
38. N-[[4-[[(trans-4-hydroxy-4-methylcyclohexyl)methyl]amino]-3-nitrophenyl]sulfonyl]-4-[2-[(2s)-2-[2-(1-methylethyl)phenyl]-1-pyrrolidinyl]-7-azaspiro[3.5]non-7-yl]-2-(1h-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide
| Molecular Weight | 890.1 g/mol |
|---|---|
| Molecular Formula | C49H59N7O7S |
| XLogP3 | 9.1 |
| Hydrogen Bond Donor Count | 4 |
| Hydrogen Bond Acceptor Count | 11 |
| Rotatable Bond Count | 12 |
| Exact Mass | Da |
| Monoisotopic Mass | Da |
| Topological Polar Surface Area | 194 |
| Heavy Atom Count | 64 |
| Formal Charge | 0 |
| Complexity | 1700 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 1 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Drugs in Development
Details:
Sonrotoclax, a miscellaneous product targeting BCL2, shows promising results in treating mantle cell lymphoma.
Lead Product(s): Sonrotoclax,Inapplicable
Therapeutic Area: Oncology Brand Name: Beqalzi
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 13, 2026
Lead Product(s) : Sonrotoclax,Inapplicable
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Fda Approves Blood Cancer Drugs from BeOne and Taiho
Details : Sonrotoclax, a miscellaneous product targeting BCL2, shows promising results in treating mantle cell lymphoma.
Product Name : Beqalzi
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 13, 2026
Details:
Zanubrutinib is a small molecule drug, which is currently being evaluated in Phase II clinical studies for the treatment of lymphoma, mantle-cell.
Lead Product(s): Zanubrutinib,Sonrotoclax,CAR-T Cell Therapy
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: BeOne Medicines
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 14, 2026
Lead Product(s) : Zanubrutinib,Sonrotoclax,CAR-T Cell Therapy
Therapeutic Area : Oncology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : BeOne Medicines
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Zanubrutinib is a small molecule drug, which is currently being evaluated in Phase II clinical studies for the treatment of lymphoma, mantle-cell.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 14, 2026
Details:
Sonrotoclax is a small molecule drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Leukemia, Lymphocytic, Chronic, B-Cell.
Lead Product(s): Sonrotoclax,Zanubrutinib
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 11, 2025
Lead Product(s) : Sonrotoclax,Zanubrutinib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Sonrotoclax is a small molecule drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Leukemia, Lymphocytic, Chronic, B-Cell.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 11, 2025
Details:
BG-71332 (Sonrotoclax) is a Other Small Molecule drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of unspecified medical condition.
Lead Product(s): Sonrotoclax,Zanubrutinib
Therapeutic Area: Undisclosed Brand Name: BG-71332
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 26, 2025
Lead Product(s) : Sonrotoclax,Zanubrutinib
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Zanubrutinib + Sonrotoclax FDC Tablet Bioavailability & Food Effect In Healthy Adults
Details : BG-71332 (Sonrotoclax) is a Other Small Molecule drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of unspecified medical condition.
Product Name : BG-71332
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 26, 2025
Details:
Sonrotoclax is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Leukemia, Lymphocytic, Chronic, B-Cell.
Lead Product(s): Sonrotoclax,Obinutuzumab
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: German CLL Study Group
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 24, 2025
Lead Product(s) : Sonrotoclax,Obinutuzumab
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : German CLL Study Group
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Sonrotoclax is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Leukemia, Lymphocytic, Chronic, B-Cell.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 24, 2025
Details:
Zanubrutinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Leukemia, Lymphocytic, Chronic, B-Cell.
Lead Product(s): Zanubrutinib,Sonrotoclax,Obinutuzumab
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: BeOne Medicines
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 27, 2025
Lead Product(s) : Zanubrutinib,Sonrotoclax,Obinutuzumab
Therapeutic Area : Oncology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : BeOne Medicines
Deal Size : Inapplicable
Deal Type : Inapplicable
Zanubrutinib, Obinutuzumab, and Sonrotoclax in Previously Untreated Patients with CLL or SLL
Details : Zanubrutinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Leukemia, Lymphocytic, Chronic, B-Cell.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 27, 2025
Details:
Sonrotoclax is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Leukemia, Lymphocytic, Chronic, B-Cell.
Lead Product(s): Sonrotoclax,Zanubrutinib
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: BeOne Medicines
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 21, 2025
Lead Product(s) : Sonrotoclax,Zanubrutinib
Therapeutic Area : Oncology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : BeOne Medicines
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Sonrotoclax is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Leukemia, Lymphocytic, Chronic, B-Cell.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 21, 2025
Details:
Sonrotoclax is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Lymphoma, Mantle-Cell.
Lead Product(s): Sonrotoclax,Zanubrutinib
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 19, 2024
Lead Product(s) : Sonrotoclax,Zanubrutinib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Sonrotoclax is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Lymphoma, Mantle-Cell.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 19, 2024
Details:
Sonrotoclax is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Leukemia, Lymphocytic, Chronic, B-Cell.
Lead Product(s): Sonrotoclax,Zanubrutinib
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase I/ Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 20, 2024
Lead Product(s) : Sonrotoclax,Zanubrutinib
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Sonrotoclax is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Leukemia, Lymphocytic, Chronic, B-Cell.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 20, 2024
Details:
Sonrotoclax is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Leukemia, Lymphocytic, Chronic, B-Cell.
Lead Product(s): Sonrotoclax,Zanubrutinib
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 15, 2024
Lead Product(s) : Sonrotoclax,Zanubrutinib
Therapeutic Area : Oncology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Sonrotoclax is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Leukemia, Lymphocytic, Chronic, B-Cell.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 15, 2024
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
ABOUT THIS PAGE
78
PharmaCompass offers a list of Sonrotoclax API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Sonrotoclax manufacturer or Sonrotoclax supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Sonrotoclax manufacturer or Sonrotoclax supplier.
A Sonrotoclax manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Sonrotoclax, including repackagers and relabelers. The FDA regulates Sonrotoclax manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Sonrotoclax API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Sonrotoclax supplier is an individual or a company that provides Sonrotoclax active pharmaceutical ingredient (API) or Sonrotoclax finished formulations upon request. The Sonrotoclax suppliers may include Sonrotoclax API manufacturers, exporters, distributors and traders.
Sonrotoclax Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Sonrotoclax GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Sonrotoclax GMP manufacturer or Sonrotoclax GMP API supplier for your needs.
A Sonrotoclax CoA (Certificate of Analysis) is a formal document that attests to Sonrotoclax's compliance with Sonrotoclax specifications and serves as a tool for batch-level quality control.
Sonrotoclax CoA mostly includes findings from lab analyses of a specific batch. For each Sonrotoclax CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Sonrotoclax may be tested according to a variety of international standards, such as European Pharmacopoeia (Sonrotoclax EP), Sonrotoclax JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Sonrotoclax USP).
